- Di sistema
- In the last decade, adoptive cell therapies and in particular car t cells have dramatically changed the therapeutic landscape of hematological malignancies, providing hope where traditional treatments had failed. Their progressive expansion into the field of solid tumors confirms the extraordinary potential of cellular immunotherapy, yet also highlights the many challenges that still need to be addressed. Resistance to therapy, tumor escape mechanisms, the hostile microenvironment that limits t cell
activity, and the persistence of treatment-related toxicities all represent major obstacles that must be overcome in order to fully realize the promise of these revolutionary strategies.